Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients

Clinical Biochemistry

Volumn 37, Issue 6 SPEC. ISS., 2004, Pages 424-428

  Oellerich, Michael ^a   Armstrong, Victor W ^b   Streit, Frank ^b   Weber, Lutz ^b   Tönshoff, Burkhard ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

Absorption monitoring; Cyclosporine; Kidney transplantation; Pediatric; Sirolimus; Therapeutic drug monitoring

Indexed keywords

ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; STEROID; TACROLIMUS;

AREA UNDER THE CURVE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PEDIATRICS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 2942560551     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.04.001     Document Type: Conference Paper

References (32)

1. Kahan B.D., Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation. 72:2001;1181-1193
2. Oellerich M., Armstrong V.W. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther. Drug Monit. 24:2002;40-46
3. Levy G., Thervet E., Lake J., Uchida K. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 73:2002;S12-S18
4. Napoli K.L., Kahan B.D. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J. Chromatogr., B, Biomed. Appl. 654:1994;111-120
5. Taylor P.J., Johnson A.G. Quantitative analysis of sirolimus (Rapamycin) in blood by high-performance liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr., B, Biomed. Sci. Appl. 718:1998;251-257
6. Holt D.W., Lee T., Jones K., Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin. Chem. 46:2000;1179-1183
7. Streit F., Armstrong V.W., Oellerich M. Rapid liquid chromatography- tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin. Chem. 48:2002;955-958
8. Salm P., Taylor P.J., Pillans P.I. Analytical performance of microparticle enzyme immunoassay and HPLC-tandem mass spectrometry in the determination of sirolimus in whole blood. Clin. Chem. 45:1999;2278-2280
9. Mahalati K., Belitsky P., Sketris I., West K., Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 68:1999;55-62
10. Mahalati K., Belitsky P., Kiberd B., et al. Absorption profiling: a novel method for monitoring neoral in kidney transplantation that reduces rejection and nephrotoxicity. Transplantation. 69:2000;S114
11. Thervet E., Pfeffer P., Scolari M.P., et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 76:2003;903-908
12. Levy G.A., Lake J.R., Beauregard-Zollinger L., Prestele H. The Neoral Phase IV Study Group Improved clinical outcomes for liver transplant recipients using cyclosporine blood level monitoring based on two-hour post-dose levels. Transplantation. 69:2000;S387
13. Cantarovich M., Elstein E., de Varennes B., Barkun J.S. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 68:1999;1839-1842
14. Sindhi R., Webber S., Venkataramanan R., et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation. 72:2001;851-855
15. MacDonald A., Scarola J., Burke J.T., Zimmerman J.J. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin. Ther. 22(Suppl. B):2000;B101-B121
16. del Mar Fernandez De Gatta M., Santos-Buelga D., Dominguez-Gil A., Garcia M.J. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin. Pharmacokinet. 41:2002;115-135
17. Ettenger R.B., Grimm E.M. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am. J. Kidney Dis. 38:2001;S22-S28
18. Mahalati K., Kahan B.D. Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet. 40:2001;573-585
19. Kahan B.D., Napoli K.L., Kelly P.A., et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin. Transplant. 14:2000;97-109
20. Hodges C.B., Maxwell H., Beattie T.J., Murphy A.V., Jindal R.M. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity. Pediatr. Nephrol. 16:2001;777-778
21. Jain A.K., Venkataramanan R., Fridell J.A., et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 8:2002;838-840
22. Fridell J.A., Jain A.K., Patel K., et al. Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. Ther. Drug Monit. 25:2003;117-119
23. Arns W. Consensus-Update zur Umstellung nierentransplantierter Patienten auf Rapamun. Dial. Aktuell. 8:2002;2-4
24. Oellerich M., Armstrong V.W., Kahan B., et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther. Drug Monit. 17:1995;642-654
25. Kahan B.D., Welsh M., Rutzky L.P. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther. Drug Monit. 17:1995;621-624
26. Filler G., Mai I., Filler S., Ehrich J.H. Abbreviated cyclosporine AUCs on Neoral-the search continues. Pediatr. Nephrol. 13:1999;98-102
27. Halloran P.F., Helms L.M., Kung L., Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 68:1999;1356-1361
28. Cooney G.F., Habucky K., Hoppu K. Cyclosporin pharmacokinetics in paediatric transplant recipients. Clin. Pharmacokinet. 32:1997;481-495
29. Melter M., Rodeck B., Kardorff R., Hoyer P.F., Brodehl J. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. Transpl. Int. 10:1997;419-425
30. Kelles A., Herman J., Tjandra-Maga T.B., Damme-Lombaerts R. Sandimmune to Neoral conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipients. Pediatr. Transplant. 3:1999;282-287
31. Weber L.T., Shipkova M., Armstrong V.W., Mehls O., Oellerich M., Tönshoff B. C2 monitoring and absorption profiling of cyclosporine for optimization of immunosuppressive therapy in pediatric renal transplant recipients. Transplant. Proc. 35:2003;2128-2130
32. Trompeter R., Fitzpatrick M., Hutchinson C., Johnston A. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Pediatr. Transplant. 7:2003;282-288